Core Viewpoint - 康沣生物-B has successfully completed the subscription agreement A, issuing 5.595 million shares at a price of HKD 5.36 per share, which represents approximately 3.90% of the H-shares issued prior to the completion of the agreement and about 2.34% of the total existing shares [1] Group 1 - The total amount raised from the subscription agreement A is approximately HKD 29.99 million, with a net amount of about HKD 29.73 million after expenses [1] - The net subscription price per share, after deducting all related expenses, is approximately HKD 5.31 [1] - The proceeds from the subscription are intended for research, production, and commercialization of minimally invasive products related to vascular intervention, respiratory intervention, and tumor intervention, as well as potential overseas business expansion for these products [1] Group 2 - The subscription agreement B has been terminated, releasing both parties from their obligations under that agreement without any claims against each other [1]
康沣生物-B(06922)完成发行559.5万股认购股份，净筹约2973万港元